$LFCR News

Is Lifecore Biomedical (LFCR) an Asymmetric Risk-Reward in Pharma Contract Manufacturing?

Lifecore Biomedical Q2 2026 Earnings Call Transcript

Lifecore Biomedical to Participate at Upcoming Industry Conferences

Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D Filing

Barrington Research Downgrades Lifecore Biomedical to Market Perform

Lifecore Biomedical: Bid Is Underwhelming

William Blair Downgrades Lifecore Biomedical to Market Perform

Lifecore Biomedical to be Acquired by Webster Equity Partners

Lifecore Biomedical To Be Acquired By Webster Equity Partners In Up To $663.7M Transaction; Stockholders May Receive Up To $9.67 Per Common Equivalent In Combined Cash And CVR At Full Performance Milestone Payments

Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business

Lifecore Biomedical to Participate at CPHI Global Conference

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary

Lifecore Biomedical Inc (LFCR) (Q2 2026) Earnings Call Highlights: Strategic Wins and Capacity ...

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical Q2 Earnings Call Highlights

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate